FDA & Mental Health: Definium Therapeutics’ DT120 (lysergide) won a second FDA Breakthrough Therapy designation for major depressive disorder, after Phase 3 Emerge results showed rapid, sustained MADRS improvement. Microbiome Trends: Probiotic supplement use surged in the US—up sharply for teens and adults—while fiber intake barely moved, raising questions about whether people are changing diets or just adding pills. Biopharma Compliance: DOJ says Veloxis ran a long kickback scheme to boost Envarsus XR prescriptions, settling for $46M+ and years of compliance oversight. Healthcare Policy/Regulation: FDA filled four senior roles permanently, including top drug and biologics leadership, aiming to stabilize the agency after earlier upheaval. Cancer Pipeline: Tyra Biosciences’ dabogratinib fell short in Phase 2 expectations, though related FGFR3-altered NMIBC data point to meaningful response rates at a 60 mg dose. Care Delivery & Workforce: Lifepoint Health is piloting AI to reduce nursing documentation burden and reprioritize patient assignments. AI in Biotech Ops: Industry leaders say AI is increasingly used for enrollment forecasting and manufacturing planning to cut rework and improve reliability. Clinical Innovation: UT Southwestern is using focused ultrasound for Parkinson’s tremors without incisions or implants. Mental Health Services: North Carolina is investing $1.9M to modernize and expand its clubhouse network for serious mental illness recovery.